**Supplemental Figure.** Azithromycin MIC among GISP isolates by clinic and through time. Each subfigure shows the mean azithromycin MIC (black line; gray ribbon shows standard deviation of data) in each clinic and month.

**Supplemental Table.** Baselines, amplitudes, and phases of seasonal macrolide use among MarketScan members. The data include 2011-2015 for overall, age groups, and regions. Ranges indicate 95% confidence intervals.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Baseline (monthly fills per 1,000 members)** | **Amplitude (monthly fills per 1,000 members)** | **Phase (months, 0.0=January 1st)** |
| Overall | 12.84 (12.40 to 13.28) \* | 4.75 (4.14 to 5.37) \* | 0.03 (-0.22 to 0.28) |
| Year |  |  |  |
|  2011 | 14.40 (13.92 to 14.88) \* | 5.41 (4.73 to 6.09) \* | 0.14 (-0.10 to 0.38) |
|  2012 | 13.56 (12.95 to 14.18) \* | 4.97 (4.10 to 5.84) \* | -0.19 (-0.52 to 0.15) |
|  2013 | 11.82 (10.87 to 12.78) \* | 5.00 (3.65 to 6.36) \* | 0.14 (-0.38 to 0.66) |
|  2014 | 10.91 (10.00 to 11.82) \* | 3.91 (2.63 to 5.20) \* | -0.17 (-0.81 to 0.47) |
|  2015 | 13.51 (13.09 to 13.93) \* | 4.56 (3.96 to 5.15) \* | 0.17 (-0.08 to 0.42) |
| Age |  |  |  |
|  10-19 | 10.99 (10.56 to 11.42) \* | 3.60 (2.99 to 4.21) \* | -0.00 (-0.33 to 0.32) |
|  20-29 | 11.01 (10.59 to 11.42) \* | 3.29 (2.71 to 3.88) \* | -0.07 (-0.41 to 0.27) |
|  30-39 | 14.16 (13.66 to 14.67) \* | 5.37 (4.65 to 6.08) \* | -0.05 (-0.31 to 0.20) |
|  40-49 | 13.74 (13.29 to 14.19) \* | 5.54 (4.90 to 6.18) \* | 0.06 (-0.16 to 0.28) |
|  50-59 | 13.79 (13.31 to 14.27) \* | 5.53 (4.85 to 6.21) \* | 0.11 (-0.12 to 0.35) |
| Region |  |  |  |
|  Midwest | 12.47 (12.00 to 12.93) \* | 4.50 (3.84 to 5.16) \* | -0.02 (-0.30 to 0.27) |
|  Northeast | 11.96 (11.45 to 12.46) \* | 4.28 (3.57 to 5.00) \* | 0.10 (-0.22 to 0.42) |
|  South | 15.14 (14.67 to 15.61) \* | 5.77 (5.10 to 6.44) \* | -0.14 (-0.36 to 0.08) |
|  West | 9.71 (9.31 to 10.11) \* | 3.73 (3.16 to 4.30) \* | 0.50 (0.21 to 0.80) \* |

\*: *p* < 0.05, Wald’s test